

IRONWOOD PHARMACEUTICALS INC
Form 8-K
August 11, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 9, 2011

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation
or organization)

001-34620
(Commission file number)

04-3404176
(I.R.S. Employer
Identification Number)

301 Binney Street
Cambridge, Massachusetts
(Address of principal
executive offices)

02142
(Zip code)

(617) 621-7722

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

(Registrant's telephone number,
including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2011, Ironwood Pharmaceuticals, Inc. (the Company) issued a press release containing an update on its business activities for the quarter ended June 30, 2011, as well as its recent business activities. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On August 9, 2011, the Company and Forest Laboratories, Inc. jointly issued a press release announcing the submission of a New Drug Application to the U.S. Food and Drug Administration for linaclotide, a guanylate cyclase type-C agonist, for the treatment of irritable bowel syndrome with constipation and chronic constipation. A copy of the press release is filed as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description |
|--------------------|---|
| 99.1 | Ironwood Pharmaceuticals, Inc. Press Release dated August 11, 2011 |
| 99.2 | Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. Press Release dated August 9, 2011 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Ironwood Pharmaceuticals, Inc.

Dated: August 11, 2011

| | | |
|-----|------------------------|-----------------------------------|
| By: | /s/ Michael J. Higgins | |
| | Name: | Michael J. Higgins |
| | Title: | Chief Operating Officer and Chief |
| | Financial Officer | |